GSK

GSK

Market cap $119B

GSK struck a deal to buy Canada's 35Pharma as the U.K. drugmaker seeks to bolster its exposure to diseases linked to obesity.

GSK PLC (LSE:GSK, NYSE:GSK) has agreed to acquire Canadian biotech 35Pharma for $950 million in cash, securing a clinical-stage drug for pulmonary hypertension that its new owner believes can improve on the safety profile of existing therapies in a market forecast to reach $18 billion by 2032. The asset at the centre of the deal is HS235, an activin signalling inhibitor that has completed phase I healthy volunteer trials and is preparing to enter studies in two forms of the disease: pulmonary arterial hypertension and pulmonary hypertension due to heart failure with preserved ejection fraction.

GSK on Wednesday agreed to buy Canadian biopharmaceutical company 35Pharma Inc for $950 million in cash.

MONTREAL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- 35Pharma, a Canada-based, private, clinical-stage biopharmaceutical company specialised in the development of novel protein-based therapeutics today announced it has entered into an agreement with GSK plc (GSK), under which GSK will acquire all of the outstanding equity interests in 35Pharma. The acquisition includes HS235, a potential best-in-class investigational medicine that has completed phase I healthy volunteer clinical trials with studies to start imminently in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF).

Frontier Biotechnologies said on Tuesday it has struck a deal with GSK , granting the British drugmaker worldwide rights to develop two small interfering RNA therapies targeting kidney diseases in an agreement that could be worth up to $1 billion.

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract.

PHILADELPHIA--(BUSINESS WIRE)--GSK's AREXVY associated with reductions in certain RSV-related risks, real world study shows.

GSK plc is a pharma worthy of a Buy rating, based on past performance and future prospects. In 2025, the company grew revenues by 7% and core EPS by 12%. GSK seems to have successfully pivoted into a "pure-play" Pharma having ditched its consumer healthcare division - despite some looming patent expiries, its pipeline looks promising enough to cope.

Citi has raised its price target for GSK PLC (LSE:GSK, NYSE:GSK) to £22.50 while maintaining a 'neutral' rating, citing a sharp rally driven by improving investor sentiment. The broker said full-year 2025 earnings per share were 2% ahead of consensus, with constant exchange rate guidance for 2026 broadly in line with expectations.

GSK secures EU approval for Nucala, an add-on maintenance treatment for chronic obstructive pulmonary disease in adults.